Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with linperlisib for recurrent/refractory peripheral T-cell lymphoma
ChiCTR2400094169Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and linperlisib in peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate and Maximum tolerated dose. Started Dec 2024; status: recruiting.
02
Drugs
camrelizumablinperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2400094169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094169.